AnPac Bio-Medical Science Co., Ltd. (ANPC) |
| 4.3 -0.14 (-3.15%) 05-19 15:59 |
| Open: | 4.57 |
| High: | 4.63 |
| Low: | 4.25 |
| Volume: | 35,704 |
| Market Cap: | 27(M) |
| PE Ratio: | -0.38 |
| Exchange: | NASDAQ Capital Market |
| Industry: | Biotechnology |
| Sector: | Healthcare |
| Technical analysis | ||||
 |
||||
| sell | buy | |||
| Resistance 2: | 4.45 |
| Resistance 1: | 4.00 |
| Pivot price: | 4.04 |
| Support 1: | 3.27 |
| Support 2: | 2.72 |
| 52w High: | 11.99 |
| 52w Low: | 2.6 |
AnPac Bio-Medical Science Co., Ltd., a biotechnology company, researches, develops, markets, and sells multi-cancer screening and detection tests using cancer differentiation analysis technology and device to corporations and life insurance companies in the People's Republic of China. It also offers physical checkup package services. The company was incorporated in 2010 and is headquartered in Lishui, the People's Republic of China.
Financials
| EPS | -11.450 |
| Book Value | 10.630 |
| PEG Ratio | 0.00 |
| Gross Profit | 0.000 |
| Profit Margin (%) | 0.00 |
| Operating Margin (%) | -871.13 |
| Return on Assets (ttm) | -52.6 |
| Return on Equity (ttm) | -243.1 |
Company news
Fri, 19 May 2023
PRN_FinancialWrapper - FinancialContent
Wed, 25 Jan 2023
Oklahoma City News - The Oklahoman - FinancialContent
Wed, 25 Jan 2023
AnPac Bio-Medical Science Announces Signing of US$5.2 Million of Definitive Investment Agreements - GlobeNewswire
Mon, 04 Oct 2021
AnPac Bio Study Shows Strong Correlation between CDA Score and Risk of Cancer and Diseases - GlobeNewswire
Thu, 30 Apr 2020
ANPC: A Blood Test for Cancer Diagnosis - Zacks Small Cap Research
Sat, 11 Oct 2025
 StockChart iOS |
 StoxlineLite iOS |
StoxlineLite iOS |
 OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |
